Mizuho Cuts Inspire Medical Systems (NYSE:INSP) Price Target to $85.00

Inspire Medical Systems (NYSE:INSP) had its target price reduced by Mizuho from $130.00 to $85.00 in a report published on Thursday morning, MarketBeat Ratings reports. They currently have an outperform rating on the stock.

A number of other equities research analysts have also issued reports on INSP. Morgan Stanley reissued an “equal weight” rating and issued a $130.00 price objective (up previously from $105.00) on shares of Inspire Medical Systems in a report on Tuesday, December 2nd. Weiss Ratings reiterated a “sell (d)” rating on shares of Inspire Medical Systems in a report on Monday, December 29th. Truist Financial cut their price target on shares of Inspire Medical Systems from $96.00 to $70.00 and set a “hold” rating for the company in a report on Thursday. Oppenheimer lowered shares of Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 22nd. Finally, Evercore reiterated an “outperform” rating and issued a $125.00 price objective on shares of Inspire Medical Systems in a research report on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Inspire Medical Systems currently has a consensus rating of “Hold” and an average target price of $108.94.

Inspire Medical Systems Stock Performance

NYSE INSP opened at $59.78 on Thursday. The business has a fifty day moving average price of $92.88 and a 200 day moving average price of $90.72. The company has a market cap of $1.74 billion, a P/E ratio of 12.00, a P/E/G ratio of 6.35 and a beta of 0.74. Inspire Medical Systems has a one year low of $53.11 and a one year high of $197.75.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.96. The business had revenue of $269.08 million during the quarter, compared to analyst estimates of $264.02 million. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.15 earnings per share. As a group, sell-side analysts predict that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of Inspire Medical Systems stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.48, for a total value of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares of the company’s stock, valued at approximately $3,320,344.08. The trade was a 7.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Inspire Medical Systems

Several institutional investors have recently bought and sold shares of the company. Texas Permanent School Fund Corp lifted its position in shares of Inspire Medical Systems by 42.2% during the 2nd quarter. Texas Permanent School Fund Corp now owns 40,042 shares of the company’s stock worth $5,196,000 after buying an additional 11,892 shares during the last quarter. Y Intercept Hong Kong Ltd grew its holdings in shares of Inspire Medical Systems by 553.1% during the third quarter. Y Intercept Hong Kong Ltd now owns 99,049 shares of the company’s stock worth $7,349,000 after purchasing an additional 83,883 shares during the last quarter. Nordea Investment Management AB acquired a new stake in shares of Inspire Medical Systems during the second quarter worth about $1,634,000. CW Advisors LLC lifted its holdings in shares of Inspire Medical Systems by 45.3% in the 2nd quarter. CW Advisors LLC now owns 49,960 shares of the company’s stock valued at $6,484,000 after purchasing an additional 15,576 shares during the last quarter. Finally, Capital Fund Management S.A. lifted its holdings in shares of Inspire Medical Systems by 44.1% in the 2nd quarter. Capital Fund Management S.A. now owns 68,663 shares of the company’s stock valued at $8,910,000 after purchasing an additional 21,021 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: INSP reported $1.65 EPS vs. $0.69 expected and revenue of ~$269M, with expanded gross margins — a near-term operational positive. Zacks: INSP Beats Q4 Estimates
• Positive Sentiment: Some firms remain constructive at reduced targets — Mizuho and Piper Sandler kept outperform/overweight stances after lowering PTs, signaling there’s still perceived upside if reimbursement issues resolve. The Fly: Mizuho PT Cut
• Neutral Sentiment: Earnings call materials and transcript are available for detailed read-through (management commentary on coding, reimbursement and 2026 guide are key). Review to judge whether guidance risks are transitory. Seeking Alpha: Q4 Earnings Call Transcript
• Negative Sentiment: Management issued a 2026 revenue outlook of $950M–$1B and flagged a coding change plus reimbursement headwinds — the primary catalyst for the selloff risk and weaker forward expectations. MSN: 2026 Revenue Outlook & Coding Change
• Negative Sentiment: Multiple analyst downgrades and price-target cuts (Wells Fargo, Baird, Jefferies, Truist and others) followed the guidance and reimbursement concerns, increasing near-term selling pressure. Investing.com: Baird, Wells Fargo Cuts
• Negative Sentiment: The stock already experienced an earlier ~8% intraday decline after the coding/guidance news, showing how sensitive the market is to reimbursement updates. Investing.com: Shares Slide 8%

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.